Literature DB >> 32865203

De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock.

Christina Routsi1,2, Aikaterini Gkoufa2, Kostoula Arvaniti3, Stelios Kokkoris1, Alexandros Tourtoglou4, Vassiliki Theodorou5, Anna Vemvetsou3, Georgios Kassianidis6, Athena Amerikanou6, Elisabeth Paramythiotou7, Efstathia Potamianou8, Kyriakos Ntorlis9, Angeliki Kanavou10, Georgios Nakos11, Eleftheria Hassou12, Helen Antoniadou12, Ilias Karaiskos2,13, Athanasios Prekates4, Apostolos Armaganidis7, Ioannis Pnevmatikos5, Miltiades Kyprianou14, Spyros Zakynthinos1, Garyfallia Poulakou2,15, Helen Giamarellou2,13.   

Abstract

BACKGROUND: De-escalation of empirical antimicrobial therapy, a key component of antibiotic stewardship, is considered difficult in ICUs with high rates of antimicrobial resistance.
OBJECTIVES: To assess the feasibility and the impact of antimicrobial de-escalation in ICUs with high rates of antimicrobial resistance.
METHODS: Multicentre, prospective, observational study in septic patients with documented infections. Patients in whom de-escalation was applied were compared with patients without de-escalation by the use of a propensity score matching by SOFA score on the day of de-escalation initiation.
RESULTS: A total of 262 patients (mean age 62.2 ± 15.1 years) were included. Antibiotic-resistant pathogens comprised 62.9%, classified as MDR (12.5%), extensively drug-resistant (49%) and pandrug-resistant (1.2%). In 97 (37%) patients de-escalation was judged not feasible in view of the antibiotic susceptibility results. Of the remaining 165 patients, judged as patients with de-escalation possibility, de-escalation was applied in 60 (22.9%). These were matched to an equal number of patients without de-escalation. In this subset of 120 patients, de-escalation compared with no de-escalation was associated with lower all-cause 28 day mortality (13.3% versus 36.7%, OR 0.27, 95% CI 0.11-0.66, P = 0.006); ICU and hospital mortality were also lower. De-escalation was associated with a subsequent collateral decrease in the SOFA score. Cox multivariate regression analysis revealed de-escalation as a significant factor for 28 day survival (HR 0.31, 95% CI 0.14-0.70, P = 0.005).
CONCLUSIONS: In ICUs with high levels of antimicrobial resistance, feasibility of antimicrobial de-escalation was limited because of the multi-resistant pathogens isolated. However, when de-escalation was feasible and applied, it was associated with lower mortality.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32865203     DOI: 10.1093/jac/dkaa375

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Evaluation of the Neonatal Sequential Organ Failure Assessment and Mortality Risk in Preterm Infants with Necrotizing Enterocolitis.

Authors:  Angela N Lewis; Diomel de la Cruz; James L Wynn; Lauren C Frazer; William Yakah; Camilia R Martin; Heeju Yang; Elena Itriago; Jana Unger; Amy B Hair; Jessica Miele; Brynne A Sullivan; Ameena Husain; Misty Good
Journal:  Neonatology       Date:  2022-03-21       Impact factor: 4.035

2.  Which Type of Empiric Antibiotic Therapy is Appropriate? A 20-Year Retrospective Study of Bloodstream Infections in Childhood Cancer.

Authors:  Andreas Meryk; Gabriele Kropshofer; Caroline Bargehr; Miriam Knoll; Benjamin Hetzer; Cornelia Lass-Flörl; Roman Crazzolara
Journal:  Infect Dis Ther       Date:  2021-03-11

3.  Characteristics and Outcomes of Bloodstream Infections in a Tertiary-Care Pediatric Hematology-Oncology Unit: A 10-Year Study.

Authors:  Davide Mattei; Valentina Baretta; Annarita Mazzariol; Laura Maccacaro; Rita Balter; Ada Zaccaron; Elisa Bonetti; Matteo Chinello; Virginia Vitale; Giulia Caddeo; Maria Pia Esposto; Vincenza Pezzella; Davide Gibellini; Gloria Tridello; Simone Cesaro
Journal:  J Clin Med       Date:  2022-02-08       Impact factor: 4.241

4.  Using Procalcitonin to Guide Antibiotic Escalation in Patients With Suspected Bacterial Infection: A New Application of Procalcitonin in the Intensive Care Unit.

Authors:  Xu Wang; Yun Long; Longxiang Su; Qing Zhang; Guangliang Shan; Huaiwu He
Journal:  Front Cell Infect Microbiol       Date:  2022-03-14       Impact factor: 5.293

5.  Salvadora persica mediated synthesis of silver nanoparticles and their antimicrobial efficacy.

Authors:  Hammad Arshad; Muhammad A Sami; Saima Sadaf; Umer Hassan
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.